e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Treatment of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity
Y. Sung, J. Ashouri, R. Zamanian, L. Chung (Stanford, Palo Alto, United States Of America)
Source:
Annual Congress 2011 - Treatment of pulmonary hypertension
Session:
Treatment of pulmonary hypertension
Session type:
Thematic Poster Session
Number:
2394
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Sung, J. Ashouri, R. Zamanian, L. Chung (Stanford, Palo Alto, United States Of America). Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity. Eur Respir J 2011; 38: Suppl. 55, 2394
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Pulmonary arterial hypertension and systemic lupus erythematosus
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Effectiveness of ²Korargin² in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Endothelium dysfunction in systemic lupus erythematosus patients with pulmonary hypertension
Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Year: 2011
Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus
Source: Eur Respir Rev 2011; 20: 277-286
Year: 2011
Early outcomes of patients with systemic lupus erythematosus and antiphospholipid syndrome after pulmonary endarterectomy
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016
Raynaud phenomenon is correlated with systolic pulmonary arterial pressure in patients with systemic lupus erythematosus
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
The nitroxidergic system state at systemic lupus erythematosus-associated pulmonary hypertension
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Examining pulmonary function measures in patients with systemic lupus erythematosus (SLE)
Source: Virtual Congress 2020 – Rare lung diseases and lung manifestations of extrapulmonary diseases
Year: 2020
Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018
Year: 2019
Cardio-pulmonary exercise testing in systemic lupus erythematosus patients
Source: Eur Respir J 2005; 26: Suppl. 49, 350s
Year: 2005
The profile of lung scintigraphy in systemic lupus erythematosus with chronic pulmonary embolism:a cross-section
Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Year: 2020
A functionally improved case of obstructive impairment caused by systemic lupus erythematosus
Source: Breathe, 17 (2) 200288; 10.1183/20734735.0288-2020
Year: 2021
Pulmonary hypertension in systemic scleroderma
Source: Eur Respir J 2003; 22: Suppl. 45, 269s
Year: 2003
Abnormalities on ventilatory efficiency during graded exercise test in juvenile systemic lupus erythematosus patients
Source: Annual Congress 2010 - Gas exchange and paediatric exercise testing
Year: 2010
Lung abnormalities in patients with systemic lupus erythematosus
Source: Eur Respir J 2001; 18: Suppl. 33, 225s
Year: 2001
Management and prognosis of respiratory manifestations revealing systemic lupus erythematosus
Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Year: 2007
Pulmonary involvement in systemic lupus erythematosus, Sjögren syndrome and mixed connective tissue disease
Source: Eur Respir Monogr 2019; 86: 106-123
Year: 2019
Pulmonary hypertension and arterial stiffness in patients with systemic scleroderma
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success?
Source: Eur Respir Rev 2011; 20: 218-219
Year: 2011
Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept